NEW YORK — Taiwanese cancer genomics firm ACT Genomics said on Thursday that it has signed an agreement to exclusively offer mProbe's OncoOmicsDx clinical cancer proteomics test in certain Asian markets.
OncoOmicsDx uses mass spectrometry to identify protein biomarkers linked to cancer progression and treatment response. Analyzing expression of these proteins along with patient genomic data can help increase the efficacy of precision medicine, according to Palo Alto-based mProbe.
Under the terms of their deal, ACT Genomics will offer OncoOmicsDx in Taiwan, Hong Kong, Macau, Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. Financial and other terms were not disclosed.
"ACT Genomics' proven track record and extensive network in Asia make them an ideal partner to accelerate the adoption of OncoOmicsDx," mProbe CEO Peter Chen said in a statement.
In July, ACT Genomics, which is majority-owned by Prenetics, inked a deal with Japanese clinical testing service provider LSI Medience to explore a personalized medicine collaboration in Japan.